U.S. cannabis laws projected to cost generic and brand pharmaceutical firms billions.
Where this comes from
- Record sourced from PubMed, PMID 36044436.
- Also identified by DOI 10.1371/journal.pone.0272492 and PMC identifier 9432746.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Legalization of cannabis by U.S. states is likely increasing the use of cannabis as an alternative to conventional pharmaceutical drugs. We examined how cannabis legalization between 1996 and 2019 affected stock market returns for listed generic and brand pharmaceutical companies and found that returns were 1.5-2% lower at 10 days after legalization. Returns decreased in response to both medical and recreational legalization, for both generic and brand drugmakers. Investors anticipate a single legalization event to reduce drugmaker annual sales by $3B on average.
Medical subject headings
- Cannabis